These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26191484)

  • 21. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
    Virlogeux V; Pradat P; Bailly F; Funingana G; Gonçalves F; Maynard M; Hartig-Lavie K; Amiri M; Zoulim F
    J Viral Hepat; 2014; 21(9):e98-e107. PubMed ID: 24612466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
    About F; Oudot-Mellakh T; Niay J; Rabiéga P; Pedergnana V; Duffy D; Sultanik P; Cagnot C; Carrat F; Marcellin P; Zoulim F; Larrey D; Hézode C; Fontaine H; Bronowicki JP; Pol S; Albert ML; Theodorou I; Cobat A; Abel L;
    PLoS One; 2015; 10(12):e0145105. PubMed ID: 26670100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.
    Sarrazin C; Susser S; Doehring A; Lange CM; Müller T; Schlecker C; Herrmann E; Lötsch J; Berg T
    J Hepatol; 2011 Mar; 54(3):415-21. PubMed ID: 21112657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
    Arends JE; van der Meer JT; Posthouwer D; Kortmann W; Brinkman K; van Assen S; Smit C; van der Valk M; van der Ende M; Schinkel J; Reiss P; Richter C; Hoepelman AI; ;
    Neth J Med; 2015 Aug; 73(7):324-30. PubMed ID: 26314715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.
    Shimada N; Tsubota A; Atsukawa M; Abe H; Ide T; Takaguchi K; Chuganji Y; Toyoda H; Yoshizawa K; Ika M; Sato Y; Kato K; Kumada T; Sakamoto C; Aizawa Y; Sata M
    Hepatol Res; 2014 Dec; 44(14):E386-96. PubMed ID: 24606109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
    Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
    Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.
    Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F
    J Viral Hepat; 2013 Jan; 20(1):59-64. PubMed ID: 23231085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.
    Fischer J; Böhm S; Scholz M; Müller T; Witt H; George J; Sarrazin C; Susser S; Schott E; Suppiah V; Booth DR; Stewart GJ; van Bömmel F; Brodzinski A; Fülöp B; Migaud P; Berg T
    Hepatology; 2012 Jun; 55(6):1700-10. PubMed ID: 22234924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.
    Cure S; Diels J; Gavart S; Bianic F; Jones E
    Curr Med Res Opin; 2012 Nov; 28(11):1841-56. PubMed ID: 23016967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms.
    Boglione L; Cusato J; De Nicolò A; Cariti G; Allegra S; Ghisetti V; Di Perri G; D'Avolio A
    Antiviral Res; 2014 Jun; 106():105-10. PubMed ID: 24726902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel.
    Maor Y; Morali G; Bashari D; Pénaranda G; Schapiro JM; Martinowitz U; Halfon P
    Haemophilia; 2013 Jan; 19(1):150-6. PubMed ID: 22913807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
    Riva E; Scagnolari C; Monteleone K; Selvaggi C; Picardi A; Mazzarelli C; Pizzigallo E; Vincenzi B; Carducci A; Antonaci S; Giannelli G; Antonelli G
    J Viral Hepat; 2012 Sep; 19(9):650-3. PubMed ID: 22863269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.
    Nadia K; Hicham E; Reda TM; Nadia T; Elarbi B; Saâd E; Mimoun Z; Saâd M
    Gene; 2015 Aug; 568(1):31-4. PubMed ID: 25958342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals.
    Sharafi H; Pouryasin A; Alavian SM; Behnava B; Keshvari M; Salimi S; Mehrnoush L; Fatemi A
    Hepat Mon; 2012 Dec; 12(12):e8387. PubMed ID: 23550102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
    Gupta AC; Trehanpati N; Sukriti S; Hissar S; Midha V; Sood A; Sarin SK
    J Med Virol; 2014 Apr; 86(4):707-12. PubMed ID: 24415442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection.
    Abdelwahab SF; Zakaria Z; Allam WR; Hamdy S; Mahmoud MA; Sobhy M; Rewisha E; Waked I
    Arch Virol; 2015 Nov; 160(11):2833-7. PubMed ID: 26280523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.